Tracer library / [68Ga]NOTA-C2

[68Ga]NOTA-C2

Also written as [Ga-68]Ga-NOTA-C2

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 1

Preclinical only, no clinical indication yet

What it is

Compound class: NOTA-conjugated anti-CD47 nanobody
Target / mechanism: CD47 PMID 36939440
Clinical application: Solid tumors including gastric cancer, for CD47 expression imaging and patient screening PMID 36939440
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	25.15% ± 10.21 n = 4 not corrected	>99%	NOTA-C2	36939440 2023 Research (Wash D C) The detailed methods for chelator conjugation, 68Ga/89Zr/177Lu-labeling, and quality control of the tracers are provided in the supplemental file. - The nondecay corrected radiochemical yield of [68Ga]Ga-NOTA-C2, [68Ga]Ga-NOTA-ABDC2, and [89Zr]Zr-DFO-ABDC2 were 25.15% ± 10.21 (n = 4), 12.85% ± 0.45 (n = 2), and 99% (n = 1), respectively.

Need this precursor?We can point you to suppliers for [68Ga]NOTA-C2, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36939440. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36939440: 'The calculated NOTA/C2 ratio was 1.3 for NOTA-C2, and the ratio for NOTA-ABDC2 was 6.6'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 36939440.